OR WAIT null SECS
The company has designed a bioanalytical offering that supports drug development, from in-vitro metabolite identification to human ADME profiling studies.
Celerion, a clinical research services company, announced it is expanding its specialized high-resolution mass spectrometry profiling capabilities in order to continue aiding sponsors throughout the process of drug metabolites becoming approved therapeutic products.
According to a June 5, 2020 press release, the company has designed a bioanalytical offering that supports drug development, from in-vitro metabolite identification to human absorption, distribution, metabolism, and excretion (ADME) profiling studies using the SCIEX TripleTOF 6600+ instrumentation along with the v.ARC 3 online radio detection and software packages.
“Celerion is pleased to provide this much-needed service to our bioanalytical clients. This metabolite identification capability rounds out our well-known ADME Human Mass Balance offering. We can now continue to work with our clients to define the radiometabolite profile of their drug following human administration to complement earlier in-vitro data and further guide drug development,” said Petra Struwe, PhD, executive director of the Zurich bioanalytical laboratory, in the press release.
“These advances enable our clients to rapidly identify and quantify metabolites from human mass balance studies to better understand the potential metabolic breakdown products of novel investigational compounds which may contribute to suboptimal pharmacokinetics and potentially toxic metabolites or even drug-drug interactions,” added Ray Farmen, PhD, vice-president of global bioanalytical sciences at Celerion, in the press release.